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High frequencies of circulating memory
T cells speciﬁc for calreticulin exon 9
mutations in healthy individuals
Morten O. Holmström 1,2, Shamaila M. Ahmad2, Uffe Klausen2, Simone K. Bendtsen2, Evelina Martinenaite2,
Caroline H. Riley3, Inge M. Svane2,4, Lasse Kjær1, Vibe Skov1, Christina Ellervik5,6,7, Niels Pallisgaard8,
Hans C. Hasselbalch1 and Mads H. Andersen2,9
Abstract
Mutations in exon 9 of the calreticulin gene (CALR) frequently occur in patients with chronic myeloproliferative
neoplasms (MPN). Patients exhibit spontaneous cellular immune responses to epitopes derived from the mutant CALR
C-terminus, and CALR-mutant-speciﬁc T cells recognize autologous CALR-mutant malignant cells. This study
investigated whether CALR-mutant-speciﬁc T cells occur naturally in CALRwt MPN-patients and in healthy individuals.
Speciﬁc immune responses against epitopes in the mutant CALR peptide sequence were detected in both CALRwt
MPN-patients and in healthy individuals. Healthy donors displayed more frequent and stronger CALR-mutant speciﬁc
T-cell responses compared to the responses identiﬁed in CALR-mutant MPN-patients. Several T-cell responses were
identiﬁed in healthy donors directly ex vivo. Importantly, by running functional analyses on live-sorted immune cells
from healthy donors, we showed that circulating CALR-mutant-speciﬁc immune cells are T-memory cells. These
ﬁndings suggest, that healthy individuals acquire a CALR exon 9 mutation, but the immune system reacts and clears
the mutant cells, and during this reaction generates CALR-mutant speciﬁc T-memory cells. We believe that these
ﬁndings provide the evidence for tumor immune surveillance in MPN.
Introduction
In 2013, two independent research groups reported on
the occurrence of somatic mutations in exon 9 of the
calreticulin (CALR) gene in 75% of patients with Janus
kinase 2 (JAK2)wt chronic myeloproliferative neoplasms
(MPN)1,2. We recently provided evidence that patients
with CALR-mutant MPN exhibit frequent, spontaneous
cellular immune responses against epitopes derived from
the mutant CALR C-terminus3, and that CALR-mutant-
speciﬁc T-cells derived from patients can recognize and
kill autologous CALR-mutant cells in a CALR-mutant
dependent manner4. As such the CALR mutations
generate an immunogenic antigen that could be used as
target for cancer immune therapy5.
As the CALR mutations are only identiﬁed in patients
with myeloid cancer, the immune system in healthy
individuals should not have been challenged with mutant
CALR epitopes, and hence should not react to stimulation
with these. Accordingly, several studies on immune
reactivity against other shared commonly occurring
mutations, such as pRAS mutations and BRAF mutations
in solid cancers, have indicated that cells from healthy
individuals fail to show spontaneous immune responses
against these neoantigens6,7. In regard to immune
responses to the BCR-ABL fusion transcript, one study
showed responses in peripheral blood mononuclear cells
(PBMC) from 3/18 healthy donors after stimulation
in vitro with autologous dendritic cells that had been
pulsed with a BCR-ABL peptide8, whereas another study
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failed to show immune responses against the transcript in
healthy individuals9. Other studies have focused on
immune responses against the somatic MYD88L265P
mutation, which occurs in several types of lymphoma10.
One study demonstrated a T-cell response, when T-cells
derived from healthy individuals were stimulated with the
MYD88L265P epitope, but the responses required two
stimulations with peptide-pulsed dendritic cells11.
Of interest, none of the above studies have demon-
strated immune responses against tumor-speciﬁc antigens
in cells from healthy individuals tested in an ex vivo set-
ting, without prior in vitro peptide stimulation. Even
more, it has never been shown, which cells in the T-cell
compartment actually harbor these neo-antigen-speciﬁc
T cells.
Given the high immunogenicity of the CALR exon 9
mutations we investigated if healthy donors display T-cell
responses speciﬁc for the CALR mutations and if so,
whether such CALR-mutant speciﬁc T cells are antigen
experienced T-memory cells (Tmem) or naive T cells
(Tnaive). The identiﬁcation of a memory response is
important, as CALR-mutant speciﬁc T cells in the Tmem
compartment suggest that healthy donors may acquire a
CALR exon 9 mutation, which is cleared by speciﬁc T-
cells and Tmem is established in the process.
This study demonstrates that healthy donors display
stronger and more frequent CALR-mutant speciﬁc T-cell
responses compared to CALR-mutant patients. Even
more, we show that the mutant CALR C-terminus har-
bors an immunogenic hotspot, and ﬁnally that CALR-
mutant speciﬁc T cells in healthy individuals are Tmem.
Materials and methods
Materials
Buffy coats from anonymized blood donors were
acquired from the blood bank at Rigshospitalet, Copen-
hagen, Denmark. Peripheral blood mononuclear cells
(PBMC) from patients with JAK2V617F-mutant MPN
were acquired after informed consent from the patient.
PBMC were isolated with Lymphoprep (Axis Shield, Oslo,
Norway) and frozen in fetal calf serum with 10% dimethyl
sulfoxide (Sigma-Aldrich, St. Louis, MO, USA). To
determine whether age might inﬂuence speciﬁc immune
responses to CALR-mutants, we isolated PBMCs from 50
healthy individuals of different ages. All participants
provided informed consent, in agreement with the Hel-
sinki Declaration, before study entry. The project was
approved by the local Ethics Committee of the Zealand
Region (Approval number SJ-175 and SJ-456).
Peptides
We chose to work with the following peptides, which
were either provided by KJ Ross-Petersen (Klampenborg,
Denmark) or Schafer-N (Copenhagen, Denmark):
CALRLong1 (RRMMRTKMRMRRMRRTRRKMRRKMS
PARP), CALRLong2 (TRRKMRRKMSPARPRT-
SCREACLQGWTEA), CALRLong3 (KMRMRRMRRT
RRKMRRKMS), and CALRLong4 (RRMRRTRRKMR
RKMSPARPRTSCREACLQGWTEA). In addition, we
used the CALRLong36 (RMRRMRRTRRKMRRKM
SPARPRTSCREACLQGWTEA) peptide, provided by
PolyPeptide Laboratories (Strasbourg, France). We also
chose to work with the following short peptides, all pro-
vided by KJ Ross-Petersen (Klampenborg, Denmark):
CALR-01 (RTRRKMRRK), CALR-02 (RTSCREACL),
CALR-03 (RTKMRMRRM), and CALR-04
(RTRRKMRRKM). The sequences of peptides and their
relation to the entire CALR-mutant C-terminal are given
in Fig. 1. To identify the immunogenic hotspot in the
mutant CALR C-terminus, we segregated the entire
mutant C-terminus into nonamer epitopes, with eight
overlapping amino acids. Thus, we generated a total of 36
nonamer peptides, which we termed the CALR library
(Supplementary Material 1). These epitopes were
acquired from Pepscan (Lelystad, Netherlands). Negative
control peptides were generated by scrambling the CALR-
mutant peptide sequence. We generated three negative
control peptides with the following sequences:
MRRTMMMMMPRRRRRRKRRSKTRAPRMRK, MERK-
MAEQRPCRKPSTRALATCRRWGSRT, and
TSMMRRRRRRKRRKMMKRM. These peptides were
provided by KJ Ross-Petersen.
Enzyme-linked immunospot assay
To analyze CALR-mutant-speciﬁc immune responses,
we employed Enzyme-Linked ImmunoSPOT (ELISPOT)
assays, according to protocols described previously12.
Immune responses were analyzed with the interferon-
gamma (IFN-γ) or tumor necrosis factor alpha (TNF-α)
ELISPOT assay. Unless otherwise stated, all experiments
were performed with the in vitro IFN-γ ELISPOT assay.
The ELISPOT assays employed 1.3 to 4 × 105 cells/well.
Unless otherwise stated, all ELISPOT experiments were
performed in triplicates. Additionally, when not otherwise
stated, ex vivo ELISPOTs were performed with thawed
PBMCs that had been allowed to rest overnight at 37 °C in
an incubator with 5% CO2 and a humidiﬁed atmosphere.
ELISPOT experiments were set-up as previously descri-
bed12. ELISPOT plates were analyzed and counted using
the ImmunoSpot S6 Ultimate Analyzer (CTL Analyzers,
Shaker Heights, OH, USA).
For the identiﬁcation of immune responses against
epitopes in the CALR library, we deviated from the
standard in vitro stimulation protocol. For cultures that
we planned to analyze for responses against the B1-C6
region of the CALR-mutant C-terminus, we performed
in vitro stimulations with the CALRLong1 peptide. For
cultures that we planned to analyze for response against
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the C7-D12 region of the CALR-mutant C-terminus, we
performed in vitro stimulation with the CALRLong2
peptide. The in vitro assays with CALRLong1 and
CALRLong2 saved time and cells, with minimal effects on
the sensitivity of the experiments, because
CALRLong1 spanned residues B1-C6, and
CALRLong2 spanned residues C7-D12.
Magnetically activated cell sorting (MACS)
CD4+ Tmem cells and Tnaive were sorted with the MACS
method, with the Memory CD4+ T-cell Isolation Kit
(order no 130–091–893) and with the Naive Pan T-cell
Isolation Kit (order no 130–097–095), respectively (both
Miltenyi Biotech, Bergish Gladbach, Germany), according
to the manufacturer’s protocols. Cells were thawed and
rested overnight, then sorted the next day. Cells were
sorted twice on a magnetic column to ensure high purity
in the enriched cells. During Tnaive isolation, we added the
optional anti-TCR γ/δ antibodies to ensure depletion of γ/
δ T cells. We analyzed the purity of the enriched fractions
by staining with Fixable Viability Stain 510, CD3-APC-
H7, CD45RO-PE, and CD45RA-APC (all BD Biosciences,
San José, CA, USA). Cells were analyzed on a FACS Canto
II ﬂow cytometer (BD Biosciences, San José, CA, USA)
equipped with FACS Diva Software. Gating strategy for
the identiﬁcation of CD3+ T cells for the phenotypic
analysis of memory cell markers is provided in Supple-
mentary Material 2.
Fluorescence-activated cell sorting (FACS) of live cells
Cells were thawed, and then rested overnight in x-vivo
medium (Lonza, Basel, Switzerland) with 5% human
serum in an incubator. The next day, cells were washed
twice in FACS buffer, then stained with the following:
LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit (Wal-
tham, MA, USA), CD45RA-APC, CD62L-PE, and CD3-
FITC (BD Biosciences, San José, CA, USA). Cells were
stained for 30min on ice, washed twice, and then resus-
pended in FACS buffer at 50 × 106 cells/mL. Next, cells
were sorted on a FACS ARIA ﬂow cytometer with
appropriate application settings and compensation con-
trols. Cell sorting was performed with a purity setting.
After sorting, cells were allowed to rest in x-vivo medium
(Lonza, Basel, Switzerland) in an incubator. After sorting
of all the cells, samples of 104 cells were analyzed to
ensure proper sorting purity. Gating strategy for the
identiﬁcation of CD3+ T cells for the phenotypic analysis
and subsequent sorting of different memory cell fractions
is provided in Supplementary Material 2. Materials and
methods for intracellular cytokine staining (ICS), estab-
lishment of T-cell cultures speciﬁc for mutant CALR
epitopes and statistical analyses are provided in Supple-
mentary Material 3.
Results
Patients with JAK2V617F-mutant MPN harbor an immune
response to mutant CALR epitopes
We scrutinized peripheral blood mononuclear cells
(PBMC) from patients with JAK2V617F-mutant poly-
cythemia vera (PV) for immune responses against the
immunogenic CALRLong1 and CALRLong2 epitopes that
are derived from the mutant CALR C-terminus3. Sur-
prisingly, 2/6 patients with PV exhibited a signiﬁcant
response against CALRLong1 (data not shown) and 3/5
had a signiﬁcant immune response against CALRLong2
(Fig. 2a), according to the distribution free resampling
method (DFR)13. CALR/JAK2 double mutants are very rare
and these mutations are generally mutually exclusive14–17.
Fig. 1 Amino acid sequences for the long and short epitopes used in this study. The sequences are shown relative to the mutant CALR C-
terminus. Every 10th amino acid is underscored to facilitate tracking
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Cells from healthy individuals display strong and frequent
immune responses against the CALRLong1 and
CALRLong2 peptides and against short CALR-mutant
epitopes
Next, we investigated whether cells from healthy indi-
viduals might also exhibit an immune response against
the CALRLong1 and CALRLong2 epitopes. Surprisingly,
cells from 20/27 (74%) individuals showed a signiﬁcant
response to CALRLong1 (Fig. 2b, c), and cells from 22/29
(76%) individuals showed a signiﬁcant immune response
to CALRLong2 (Fig. 2b, c). Using ICS, 5 and 4 healthy
individuals were analyzed for responses against CALR-
Long1 (Fig. 2d) and CALRLong2 (Fig. 2e), respectively.
Stimulation of PBMC with mutant CALR epitopes lead to
increased production of TNF-α and IFN-γ from CD4+ T-
cells. The responses were only borderline signiﬁcant,
probably due to low sample size.
Given these highly surprising results, we investigated
the immunogenic potential of three CALR-mutant non-
amer epitopes (CALR-01, CALR-02, and CALR-03) and
one CALR-mutant decamer epitope (CALR-04). CALR-02
induced responses in cells from 4/5 individuals, and
CALR-03 and CALR-04 induced responses in cells from
one individual each (Fig. 2f). Furthermore, we tested
cytokine release in three donors against CALR-02 using
ICS (Fig. 2g). However, the difference in cytokine release
between stimulated and unstimulated cells did not reach
statistical signiﬁcance.
Fig. 2 Spontaneous CD4+ and CD8+ T-cell responses against several epitopes in the mutant CALR C-terminus in healthy donors. a Cells
from ﬁve patients with JAK2V617F-mutant MPN were analyzed for responses against CALRLong2 in an IFN-γ ELISPOT with varying effector cell
concentrations. (Left) The number of spot-forming cells in control wells was subtracted from the number of spot-forming cells in peptide-stimulated
wells. (Right) Example of an ELISPOT performed with PBMCs from one patient that was JAK2V617F+; PBMCs were stimulated with or without the
CALRLong2 peptide. b The numbers of healthy individuals that showed speciﬁc immune responses to CALRLong1 and CALRLong2 peptides in IFN-γ
ELISPOT. DFR-deﬁned and DFR2x-deﬁned responses are indicated. c Example of wells from healthy individuals that responded to (left) CALRLong1
and (right) CALRLong2. d, e Intracellular cytokine staining performed in cells from healthy individuals shows that CD4+ T-cells were double-positive
for TNF-α and IFN-γ, after stimulation with either: d CALRLong1 (n= 5), or e CALRLong2 (n= 4), compared to a negative control scrambled peptide. f
(Left) Cells from ﬁve healthy individuals were analyzed for spontaneous immune responses against three nonamer epitopes (CALR-01, CALR-02, CALR-
03) and one decamer epitope derived from the CALR-mutant C-terminus. No samples showed DFR-deﬁned responses against CALR-01; 4/5 samples
responded to CALR-02; 1/5 samples responded to CALR-03; and 1/5 samples responded to CALR-04. (Right) Example of a response against CALR-02. g
Cells from three healthy individuals that showed immune responses against CALR-02. Intracellular staining shows TNF-α and IFN-γ production in
CD4+ and CD8+ T-cells stimulated with CALRLong2, compared to unstimulated cells. Error bars display standard error of the mean. *p ≤ 0.05
according to the DFR rule
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Screening for immune responses against nonamer
epitopes in the mutant CALR C-terminus identiﬁes an
immunogenic hotspot sequence
Given the remarkably high frequency of responses
against the CALR-mutant epitopes we veriﬁed that there
was no homology between the 44 amino acid mutant
CALR sequence and other known epitopes by the Basic
Local Alignment Search Tool (BLAST)18 using the blas-
tpprogramme and the non-redundant protein sequences
(nr) database. We next examined whether the CALR-
mutant speciﬁc immune responses might be directed
towards a certain part of the mutant sequence. Hence, we
divided the 44-amino acid mutant C-terminus that is
shared between the majority of CALR-mutant patients,
into nonamer epitopes, with eight overlapping amino
acids (Supplementary Material 1). Accordingly, we gen-
erated 36 nonamer epitopes, and analyzed PBMCs from
ten healthy individuals for immune responses against each
of these epitopes. We observed immune responses against
all parts of the mutant CALR sequence (Supplementary
Material 4); however, we could clearly identify an
immunogenic hotspot located in the B6 to C7 region.
Thus, although all parts of the mutant CALR C-terminus
were immunogenic, the most immunogenic part (the
hotspot) was located in the second quartile of the mutant
C-terminus.
Cells from healthy subjects display strong, frequent
immune responses against peptides spanning the entire
mutant CALR C-terminus
As the B7-C6 hotspot sequence seemed to be highly
immunogenic we merged the sequence into one long
peptide (CALRLong3) and analyzed the immunogenicity
of this epitope. Not surprisingly, 12/14 healthy donors
harbored a response to CALRLong3 (Fig. 3a). However,
our analysis of the CALR library showed that immune
responses are identiﬁed agains all parts of the C-terminus.
Therefore, we analyzed immune responses against
CALRLong4, which spans the 34 most C-terminal amino
acids in the mutant C-terminus, and CALRLong36, that
spans all 36 amino acids in the CALR-mutant C-terminus.
The immunogenicity of the latter was of particular
interest, as this peptide is used in the phase I clinical
vaccination trial currently running at our institution
(NCT03566446). Both CALRLong4 and CALRLong36
incited frequent and strong responses (Fig. 3a). We then
performed ELISPOT assays on PBMC plated directly
ex vivo and allowed to incubate in the ELISPOT plate for
22 h. Ex vivo responses against CALRLong4 was found in
4/5 analyzed samples, and three samples displayed a
DFR2x-deﬁned signiﬁcant response (Fig. 3b). Likewise, 2/
2 analyzed samples showed an ex vivo response against
CALRLong36 (Fig. 3c). As the CALRLong4 and CALR-
Long36 peptides are long peptides and, therefore, need
antigen processing for presentation on the cell surface, the
22 h ex vivo ELISPOT may not show the full response to
the mutant epitopes. As such, we performed 72 h ex vivo
IFN-γ ELISPOT in PBMC from 11 healthy donors, (Fig.
3d) and TNF-α ELISPOT in PBMC from ten healthy
donors (Fig. 3e). All 11 donors had an IFN-γ response,
and six displayed a TNF-α response, once more demon-
strating that the CALR-mutant epitopes are highly
immunogenic, and the responses identiﬁed are indeed
elicited by circulating CALR-mutant-speciﬁc T-cells. By
using ICS on in vitro stimulated cultures to investigate the
phenotype of the cytokine-producing cells stimulated with
CALRLong3, CALRLong4 and CALRLong36 we found
that it is mainly CD4+ T-cells that are activated upon
antigen stimulation (Fig. 3f).
The frequency of CALR-mutant-speciﬁc immune responses
does not change with age
As the median age of diagnosis of CALR-mutant MPN-
patients is 47–57 years16,19–22, we wondered if the
emergence of CALR-mutant MPN could be explained by
an age dependent loss of CALR-mutant speciﬁc immune
response. Hence, we analyzed the speciﬁc responses
against CALRLong1 and CALRLong4 in PBMC from 25
healthy individuals with a median age of 19 years (range
18–21 years) and in PBMC from 25 healthy individuals
with a median age of 57 years (range 50–64 years). No
difference in frequency nor amplitude of responses
against CALRLong1 and CALRLong4 was identiﬁed
between the two age deﬁned cohorts (Supplementary
Material 5A, 5B).
In total we have analyzed the CALR- mutant speciﬁc
immune responses in a vast amount of healthy subjects:
Of 74 subjects analyzed for response against CALRLong1,
54 (78%) exhibited a DFR-deﬁned signiﬁcant immune
response, and 24 (32%) exhibited a DFR2x-deﬁned sig-
niﬁcant response. The responses against CALRLong4
were even more frequent; of 110 subjects analyzed, PBMC
from 98 (89%) exhibited a DFR-deﬁned signiﬁcant
response and 60 individuals (55%) exhibited a DFR2x-
deﬁned signiﬁcant response.
CALR-mutant speciﬁc immune responses are identiﬁed in
CD4+ Tmem, but not Tnaive cells
Given the high frequencies and amplitudes of CALR-
mutant-speciﬁc T-cell responses in healthy individuals,
we speculated that these T-cell responses might be attri-
butable to Tmem rather than Tnaive. To investigate this
hypothesis, we isolated CD4+ Tmem from a healthy indi-
vidual that had shown a clear CALRLong4-speciﬁc T-cell
response. In these CD4+ Tmem enriched cells, we readily
detected a strong in vitro immune response against
CALRLong4 (Fig. 4a). Similarly, we isolated enriched
Tnaive from the same donor, and these cells did not show a
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Fig. 3 (See legend on next page.)
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speciﬁc response to CALRLong4 in vitro (Fig. 4b). How-
ever, we detected a CALRLong4-speciﬁc immune
response in the unsorted PBMC fraction and in the Tnaive-
depleted fraction. Next, we used FACS to enrich PBMC
from two healthy donors for T effector memory T-cells
(TEM), which were stimulated ex vivo in ELISPOT with
CALRLong4. Strong ex vivo immune responses in the
highly pure TEM cell fractions were detected (Fig. 4c).
Ex vivo CALR-mutant-speciﬁc immune responses reside
primarily in the CD4+ Tmem compartment
As the use of FACS for sorting TEM cells can potentially
interfere with cell functionality, we looked further into the
CALR-mutant-speciﬁc T-cell responses by sorting
PBMCs from three healthy individuals using MACS to
enrich for CD4+ Tmem and Tnaive. The enrichments were
based on negative selection; i.e., the cells of interest were
not treated with antibodies that could either activate or
inactivate the cells. We investigated the enriched T cells
with an ex vivo IFN-γ ELISPOT assay for responses
against CALRLong1, CALRLong4, and CALRLong36. The
CD4+ Tmem from all donors displayed strong CALR-
mutant-speciﬁc T-cell responses, mainly against CALR-
Long4 and CALRLong36. In samples from two indivi-
duals, the enriched Tnaive fraction did not display any
immune responses (Fig. 5a, b). However, in one indivi-
dual, both the CD4+ Tmem fraction and the Tnaive fraction
displayed responses against the three mutant epitopes
(Fig. 5c). However, the strongest immune response was
identiﬁed in the Tmem fraction.
To clarify whether these results might be reproducible
by using another enrichment procedure, we performed
FACS live-cell sorting to isolate either Tmem (CD3
+,
CD62L+, CD45RA-; CD3+, CD62L−, CD45RA+; and
CD3+, CD62L-, CD45RA−) or Tnaive (CD3
+, CD62L+,
CD45RA+) fractions. Next, we analyzed the enriched
fractions and the unsorted cells using ex vivo IFN-γ
ELISPOT to identify spontaneous immune responses
against CALRLong4. Once more, we detected responses
in enriched Tmem, whereas no signiﬁcant responses were
detected in the Tnaive fraction (Fig. 6a). To determine
whether the cryopreservation of PBMC might have
inﬂuenced the responses, we isolated PBMC from freshly
drawn blood from a healthy individual with a known
response to CALRLong4. The PBMC were rested over-
night and then live-sorted with FACS and assayed in an
ex vivo IFN-γ ELISPOT. Upon stimulation with CALR-
Long4 and CALRLong36, we once more detected cyto-
kine release from Tmem, but not from Tnaive (Fig. 6b).
Next, Tmem from the cell sorting were stimulated in vitro
for 7 days with the CALRLong4 peptide and analyzed with
ICS to investigate the phenotype of the responding Tmem.
Accordingly, we demonstrated that both CD4+ and CD8+
Tmem responded to stimulation with CALRLong4 (Fig.
6c). Due to the low yield of Tnaive from the cell sorting
procedure, we did not analyze potential CALRLong4-
speciﬁc responses in Tnaive with ICS.
CALR-mutant-speciﬁc immune responses reside primarily
in the TEM and TCM fractions
As the CALR-mutant speciﬁc T cells clearly reside within
the Tmem compartment we then examined which of the
cells in this compartment are the most reactive to the
CALR-mutations. Hence, we used FACS live-cell sorting to
isolate four different CD3+ T-cell fractions: TEM (CD3
+,
CD62L−, CD45RA−), T central memory cells (TCM: CD3
+,
CD62L+, CD45RA−), terminally differentiated memory
cells (TEMRA: CD3
+, CD62L−, CD45RA+), and Tnaive
(CD3+, CD62L+, CD45RA+). Then, we analyzed
CALRLong4-speciﬁc immune responses in sorted cells
using ex vivo IFN-γ ELISPOT assays. Cells from two dif-
ferent individuals were analyzed. The ﬁrst sample showed
the highest antigen-speciﬁc immune responses in the TEM
and TEMRA fractions (Fig. 7a, top). However, due to the
scarcity of cells, we only analyzed TEM cell responses in
duplicate wells and TEMRA cell responses in a single well.
We also identiﬁed some reactivity in the TCM fraction. The
lowest cytokine release was identiﬁed in the Tnaive fraction.
Purity analyses of the enriched fractions invariably showed
very high purity (Fig. 7a, bottom). Repeating the sorting
procedure in another donor we got a higher cell yield and
were able to analyze TEM, TCM, and Tnaive fractions in
(see ﬁgure on previous page)
Fig. 3 In vitro and ex vivo immune responses against epitopes that spanned the entire mutant C-terminus. a (Left) In vitro IFN-γ ELISPOT
results show the number of cells that speciﬁcally responded to CALRLong3, CALRLong4, and CALRLong36 peptides. The DFR-deﬁned and DFR2x-
deﬁned responses are indicated below the graph. Example of responses against CALRLong3 (left), CALRLong4 (middle), and CALRLong36 (right). b
(Left) Ex vivo 22 h IFN-γ ELISPOT responses against CALRLong4 in cells from ﬁve healthy individuals; (right) example of a response. c (Left) Ex vivo 22 h
IFN-γ ELISPOT responses against CALRLong36 in cells from two healthy individuals. d Ex vivo 72 h IFN-γ ELISPOT against CALRLong4 in cells from 11
healthy individuals, with wells displaying a representative response shown to the right. e Ex vivo 72 h TNF-α ELISPOT against CALRLong4 in cells from
ten healthy individuals, with wells displaying a representative response shown to the right. f Intracellular cytokine staining of cells from healthy
individuals depicts IFN-γ/TNF-α-double-positive CD4+ T-cells stimulated with either CALRLong3 (left), CALRLong4 (middle), or CALRLong36 (right).
Cells from ten healthy donors were analyzed for responses against CALRLong4, and cells from ﬁve healthy donors were analyzed for response against
CALRLong3 and CALRLong5. Error bars display standard error of the mean. *p ≤ 0.05 according to the DFR rule. **p ≤ 0.05 according to the DFR2x rule
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triplicate experiments. Both the TCM and TEM fractions of
this sample displayed very strong CALRLong4-speciﬁc
immune responses. In contrast, the Tnaive and TEMRA
responses were very weak (Fig. 7b).
CALR-mutant speciﬁc T-cell cultures from CD4+ Tmem
recognize several epitopes from the mutant CALR C-
terminus and upregulate CD107a upon antigen
stimulation
We have previously demonstrated that it is possible to
isolate and expand CALR-mutant speciﬁc T cells from
CALR-mutant MPN-patients. To further verify, that CALR-
mutant speciﬁc T cells in healthy donors are indeed antigen
experienced Tmem, we chose to analyze whether it is possible
to isolate and expand CALR-mutant speciﬁc T cells from
the Tmem compartment of healthy donors. Hence, using
MACS we enriched CD4+ Tmem from PBMC from two
different healthy donors. The cells were enriched twice to
ensure a high purity of cells (Fig. 8a, left and 8c, left). Next,
the CD4+ Tmem were stimulated three times with auto-
logous DCs that were either pulsed with CALRLong1 or
CALRLong4 peptide. Antigen responses were measured at
day 5 after each DC stimulation using ICS. A total of three
DC stimulations were performed. Due to scarcity of T cells,
the CALRLong1 speciﬁc culture was expanded after the
third DC stimulation using our rapid expansion protocol
with high dose IL-2. The two T-cell cultures responded with
cytokine release (Fig. 8a, c, middle panel), and enhanced
expression of the degranulation marker CD107a upon sti-
mulation with antigen (Fig. 8a, c, right panel). This last
ﬁnding is especially noteworthy, as CALR-mutant speciﬁc
T cells from patients were shown to display speciﬁc
Fig. 4 CALR-mutant-speciﬁc T-cell responses in different T-cell
compartments. a PBMCs from healthy individuals were enriched for
CD4+ Tmem with MACS. Enriched cells, CD4
+ Tmem-depleted cells, and
unsorted cells were analyzed in a standard IFN-γ ELISPOT. (Middle) The
number of spots per T-cell fraction and (top) a representative
photograph of wells stimulated with either CALRLong4 or a negative
scrambled peptide. (Bottom) Purity analyses of CD3+ gated cells in
corresponding cell fractions. ELISPOT assays were performed in
triplicate. b PBMCs from healthy individuals were enriched for Tnaive
cells with MACS. Enriched cells, Tnaive-depleted cells, and unsorted
cells were analyzed in a standard IFN-γ ELISPOT. (Middle) The number
of spots per T-cell fraction; (top) a representative photograph of wells
stimulated with either CALRLong4 or a negative scrambled peptide.
(Bottom) Purity analyses of CD3+ gated cells in corresponding cell
fractions. ELISPOT assays were performed in triplicates. c PBMCs from
healthy individuals were enriched for T effector memory cells (TEM)
(CD3+, CD45RA-, CD62L−) with FACS, and analyzed in an ex vivo IFN-γ
ELISPOT. (Left) The number of spot-forming cells and a representative
photograph of wells stimulated with either CALRLong4 or a negative
scrambled peptide. (Right) FACS plots of unsorted PBMCs and TEM-
enriched fractions show the purity of TEM-enriched fractions in CD3
+
gated cells. Error bars display standard error of the mean
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cytotoxicity to autologous CALR-mutant cells through
upregulation of CD107a4. Finally, by analyzing immune
responses from the two T-cell cultures, we demonstrated
that the CALR-mutant speciﬁc T cells recognize several
epitopes in the mutant C-terminus (Fig. 8b, d). Thus, anti-
gen experienced T cells isolated and expanded from healthy
donors do secrete cytokines upon stimulation with several
epitopes from the mutant CALR C-terminus, and these
T cells are potentially able to kill CALR-mutant cells.
Discussion
We previously described in detail that the immune
system of CALR-mutant patients speciﬁcally reacts to the
mutant CALR C-terminus3. Even more, we showed that
CALR-mutant speciﬁc T cells cloned from CALR-mutant
patients recognize and kill autologous CALR-mutant
target cells in a CALR-mutant-dependent manner4.
However, in CALRwt individuals, the immune system
should not have been challenged with mutant CALR
epitopes, and accordingly such individuals should not
display a CALR-mutant speciﬁc immune response. Sur-
prisingly, we identiﬁed CALR-mutant speciﬁc immune
responses in several JAK2V617F-mutant MPN-patients.
Although we did not test whether these patients also
carried CALR mutations, we speculated that it would be
highly unlikely as JAK2 and CALR double mutants are
rare14–16. This ﬁnding lead us to analyze CALR-mutant
speciﬁc responses in healthy donors, and we were sur-
prised to ﬁnd even stronger and more frequent responses
in healthy donors compared to the responses identiﬁed by
us in CALR-mutant MPN-patients3. The stronger and
more frequent responses might be explained by the theory
of cancer immuno-editing;23 cancer cells may be cleared
by the immune system (in healthy individuals), be held in
equilibrium by the immune system (in the MPN-setting;
patients with essential thrombocythemia), or escape the
immune system and enter into the metastatic dis-
seminated stage (in the MPN-setting; patients with mye-
loﬁbrosis)23,24. By following this notion, the data
described here implies, that healthy individuals are able to
clear cells harboring the CALR-mutation and, accordingly,
this tumor cell elimination generates CALR-mutant spe-
ciﬁc Tmem. Interestingly, Tubb et al.
25 recently isolated
CALR-mutant speciﬁc CD8+ T cells from peripheral
blood in healthy donors using HLA-I tetramers. Even
though this study did not provide data on the frequency of
healthy donors harboring CALR-mutant speciﬁc T cells,
and, most importantly, did not investigate the phenotype
of such T cells, it still supports our ﬁndings of immune
responses against mutant CALR in healthy individuals.
Fig. 5 CALR-mutant-speciﬁc ex vivo responses in both CD4+ Tmem and Tnaive compartments. PBMCs from three healthy individuals (a, b, and c)
were enriched for CD4+ Tmem and Tnaive with MACS. Enriched cells were analyzed in an ex vivo IFN-γ ELISPOT. (Top) Photographs of wells stimulated
with either CALRLong4 or a negative scrambled peptide; (middle) analysis of purity of the different cell fractions in CD3+ gated cells; (bottom) graph
shows the number of cells speciﬁc for CALRLong1, CALRLong4, and CALRLong36. The number of peptide-speciﬁc cells was calculated by subtracting
the number of spots in wells stimulated with a scrambled negative control peptide from the number of spots in peptide-stimulated wells. Error bars
display standard error of the mean
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As such, no studies have investigated the phenotype of
neo-antigen-speciﬁc T cells in healthy donors, and only a
limited number of studies have investigated the memory
phenotype of T cells that display reactivity to tumor-
associated antigens. Pittet et al.26 investigated the phe-
notype of CD8+ T cells from healthy individuals with a
reactivity against the melanoma associated antigen
MART-1 and found the speciﬁc T cells to be Tnaive. In
contrary we describe by several different means, that
Tmem are activated both in vitro and ex vivo upon sti-
mulation with the mutant CALR antigen. Importantly, we
further describe that T-cell cultures derived from high
purity Tmem fractions from two healthy donors reacted
against several epitopes in the mutant CALR C-terminal.
The data presented in this study imply that the immune
system in healthy individuals has been exposed to CALR-
mutant cells. Given the exquisite immunogenicity of these
mutations, the CALR-mutant cells have been cleared by
the immune system before the establishment of overt
malignancy and, consequently T-cell memory to the
CALR-mutations has been generated.
We did not only detect frequent and strong T-cell
responses among in vitro stimulated T cells, but also
directly ex vivo. These ex vivo responses are especially
remarkable as it, even in cancer patients, is rare to detect
tumor-associated antigen-speciﬁc T-cells ex vivo by tet-
ramer staining or ELISPOT27. As such, it is unusual for
cells from healthy individuals to display a high frequency
of speciﬁc immunity against a cancer neo-antigen.
Given the high frequency of responses to the mutant
antigens we veriﬁed that the CALR mutations do not share
sequence homology with any other known epitope. We also
ordered peptides from three different peptide providers (see
Materials and methods) in order to rule out the possibility
of peptide impurities as an explanation to the T-cell
responses. Furthermore, the established T-cell cultures
Fig. 6 CALR-mutant-speciﬁc responses in FACS-sorted Tmem, but not in Tnaive. a PBMCs from a healthy individual were enriched for Tmem (CD3
+,
CD62L+, CD45RA− or CD3+, CD62L−, CD45RA+ or CD3+, CD62L−, CD45RA−) and Tnaive (CD3
+, CD62L+, CD45RA+). Cells were analyzed in an ex vivo
IFN-γ ELISPOT to determine the numbers of spot-forming cells (left) in each cell fraction that responded to CALRLong4. (Middle) photographs of wells.
(Right) Analysis of purity of the different T-cell fractions in CD3+ gated cells. b PBMCs isolated from freshly drawn blood from an older healthy
individual with a clear CALRLong4-speciﬁc response were rested overnight in an incubator. Cells were sorted into Tmem and Tnaive, and analyzed for
peptide-speciﬁc T-cell responses in an ex vivo IFN-γ ELISPOT assay. The number of spot-forming cells was determined in each cell fraction for cells
stimulated with (left) CALRLong4 or (middle) CALRLong36. (Right) FACS purity analysis results. Due to difﬁculties in separating Tnaive (CD3
+, CD62L+,
CD45RA+) and TEMRA (CD3
+, CD62L-, CD45RA+) cells, the sorting gates were set differently from those set in a, to avoid contamination of Tnaive and
TEM enrichments. c Tmem isolated in b were intracellularly stained after one week of in vitro stimulation with the CALRLong4 peptide. Panel shows the
cytokines produced by (left) CD4+ T-cells and (right) CD8+ T-cells upon stimulation with CALRLong4 or a negative control scrambled peptide. Error
bars display standard error of the mean
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Fig. 7 CALR-mutant-speciﬁc responses in both TEM and TCM. a PBMCs from a healthy individual were enriched for T effector memory cells (TEM:
CD3+, CD62L- CD45RA−), T central memory cells (TCM: CD3
+, CD62L+, CD45RA-), TEMRA (CD3
+, CD62L−, CD45RA+), and Tnaive (CD3
+, CD62L+,
CD45RA+). Cells were analyzed in an ex vivo IFN-γ ELISPOT for responses against CALRLong4. (Top) Representative wells for each cell fraction show
responses to both CALRLong4 and a scrambled negative control peptide; (middle) graph shows the numbers of spot-forming cells in each cell
fraction. (Bottom) Analysis of purity of the different T-cell fractions in CD3+ gated cells. Due to cell scarcity, TEM and TEMRA responses were measured in
duplicate and in a single experiment, respectively. TCM and Tnäive responses were measured in triplicate. b PBMCs from healthy individuals were
sorted and analyzed as described above. (Top) Representative wells for each cell fraction show responses to both CALRLong4 and a scrambled
negative control peptide. (Bottom) Graph shows the number of spot-forming cells in each cell fraction. Due to cell scarcity, we did not perform purity
analyses. TEMRA responses were analyzed in a single experiment, but all other cell fractions were analyzed in triplicate. Error bars display standard error
of the mean
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derived from Tmem recognized several epitopes in the
mutant CALR C-terminus, demonstrating that the observed
responses indeed are CALR-mutant speciﬁc T-cell
responses.
The high frequency of CALR-mutant-speciﬁc immune
responses observed in healthy individuals samples raises
the question why some individuals develop CALR-mutant
MPN. The functionality of the immune system is believed
to decline with age, and the median age at diagnosis of
CALR-mutant MPN is reported to be 47–57 years16,19–22.
Therefore, we examined the frequency of immune
responses to the CALR-mutant C-terminus in two age
deﬁned cohorts (median ages: 19 years vs. age 57 years).
However, no differences were found in neither frequency
nor response between to two age deﬁned cohorts.
As the CALR mutations are highly immunogenic it
might seem paradoxical, that the disease is not cleared by
the immune system. However, there are several explana-
tions to the paradoxical emergence of CALR-mutant
MPN. Firstly, it was recently shown, that CALR-mutant
patients display lower levels of human leukocyte antigen-
I28, and patients with MPN show increased levels of
myeloid derived suppressor cells29. Although these
explanations could partially clarify why CALR-mutant
cells are able to evade immune-mediated destruction, it
does not explain why CALR-mutant cells are initially able
to establish themselves in the bone marrow, evade
immune-mediated destruction, expand and develop overt
CALR-mutant MPN. We are currently investigating a
cohort of healthy individuals for low-burden CALR-
mutations and hope that we thereby may identify healthy
individuals with low-burden CALR-mutation. A thorough
analysis of the immune constitution of such individuals
might add important new information on the develop-
ment and evolution of CALR-mutant MPN, which could
potentially be prevented by therapeutic cancer vaccination
with CALR-mutant epitopes.
In conclusion, we have demonstrated that a majority of
healthy individuals harbor immune cells that display
Fig. 8 Establishment of two T-cell cultures speciﬁc for mutant
CALR epitopes. a (Left) Purity analysis of isolated CD4+ T-memory
cells with cells stained for CD45RO (top, left) and cells that were
unstained (below, left). The percentages depict the amount of
CD45RO+ cells from the CD3+ fraction. After three stimulations with
autologous DC cells were analyzed for cytokine release against
CALRLong4 (top, middle) and scrambled negative control peptide
(below, middle). Cells were also analyzed for expression of CD107a
upon stimulation with CALRLong4 (top, right) and negative control
peptide (below, right). b The T-cell culture was analyzed for responses
against the CALR library and several other CALR-mutant epitopes with
the amount of spots shown (top), and representative wells displayed
(below). c CD4+ T-memory cells were isolated from another donor and
used to establish a T-cell culture speciﬁc for the CALRLong1 epitope.
Purity analysis (left), cytokine release (middle), and CD107a
upregulation were analyzed as in a. d The CALRLong1 speciﬁc T-cell
culture was analyzed for responses against the CALR library. We
identiﬁed responses against several short epitopes from the CALR
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CALR-mutant-speciﬁc T-cell responses, and that the
frequency and amplitude of these responses are higher
than in CALR-mutant patients. Neither do the frequency
nor amplitude of responses depend on age. Moreover, we
show that the majority of the immune responses are
attributed to Tmem, particularly cells of the TEM and TCM
compartments. In essence this demonstrates that the
immune system in healthy individuals has eliminated
tumor cells and generated T-cell memory, thus demon-
strating the ﬁrst of the three E’s - elimination - in the
theory of cancer immuno-surveillance/editing24.
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